Business Wire

SPIE Photonics West 2026 Opens for Registration

1.10.2025 20:48:00 CEST | Business Wire | Press Release

Share

Registration has opened for SPIE Photonics West 2026, which will run from 17 to 22 January at San Francisco’s Moscone Center. The largest annual conference and exhibition in optics and photonics, Photonics West brings together researchers, innovators, engineers, and business leaders from across the globe for an exciting week of research sharing, thought leadership, and innovation-inspiring exchanges. With more than100 technical conferences and 150 special events complementing the 1,200-plus companies at the exhibitions, the dynamic week will once again provide all attendees with an exhilarating experience that showcases the best of photonics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251001765437/en/

A bustling Moscone Center in San Francisco during 2025's SPIE Photonics West.

SPIE Photonics West will have six major application areas presenting the latest technologies and discoveries that utilize optics and photonics. BiOS highlights new research in biophotonics, biomedical optics, and imaging for diagnostics and therapeutics; LASE focuses on the laser industry and its diverse applications; OPTO covers optoelectronics, photonic materials, and optical devices; Quantum West features quantum 2.0 technologies from quantum sensing and information systems to quantum-enabled materials, devices, and biology; AR | VR | MR focuses on augmented, virtual, and mixed reality and the vital role that optics and photonics play in hardware and headset development; and, new in 2026, Vision Tech will highlight emerging vision technologies including AI, 3D sensing, hyperspectral and multispectral imaging, and embedded vision.

The five exhibitions during Photonics West feature more than 1,200 companies, with industry-focused presentations, product launches, live demonstrations, and cutting-edge technologies representing the diverse applications of a healthy and growing photonics industry.

The BiOS Expo, featuring new and transformative technologies for biomedical optics and healthcare applications, runs 17-18 January. The AR | VR | MR Expo — with a focus on headsets and hardware for XR applications — takes place on 20-22 January. The Quantum West Expo, 20-22 January, will showcase international providers of the latest quantum-enabled and -enabling technologies. The newest exhibition at Photonics West, Vision Tech Expo, which runs 20-22 January, will highlight innovative vision, sensing, and imaging technologies. And the Photonics West Exhibition, running 20-22 January, encompasses the latest products from laser manufacturers and suppliers as well as other innovative optics and photonics devices, components, systems, and services. A dynamic, informative SPIE industry program offers a critical understanding of the markets and applications shaping the photonics industry.

Complementing the wide-ranging SPIE industry program are the Quantum West Business Summit, addressing the latest efforts that are moving quantum technologies to market; the popular SPIE Prism Awards gala evening, honoring the best industry innovations; and the fast-paced SPIE Startup Challenge, highlighting new and emerging companies.

“We’re thrilled to welcome the global photonics community back to San Francisco for SPIE Photonics West 2026,” said SPIE Senior Director of Events and Exhibition Services Jenifer Dodds. “This is where the future of photonics takes center stage. Year after year, I’m amazed by the buzz on the show floor and the groundbreaking technologies our exhibitors unveil. From the latest in biomedical optics, to quantum breakthroughs and next-generation laser solutions, attendees will walk away energized, inspired, and equipped with new connections and opportunities to accelerate their work.”

An impressive lineup of plenary speakers will spotlight the latest innovative research breakthroughs throughout the week. Speakers include University of Colorado at Boulder’s Scott Diddams; Icahn School of Medicine at Mount Sinai’s HelenFeltovich; Cornell University’s Debdeep Jena; Max-Planck-Institut für Biochemie’s Ralf Jungmann; ICFO’s Frank Koppens; Oura’s Heli Koskimäki; University of Sydney’s Sergio Leon-Saval; McGillUniversity’s Odile Liboiron-Ladouceur; Baylor College of Medicine’s Irina Larina; Stanford University’s Jonathan T.C. Liu; Aston University’s Igor Meglinski; OmniVision Technologies’ Bo Mu; Vision Markets’ Ronald Mueller; UCLA’s Prineha Narang; the United States Army SBIR|STTR’s Portfolio Manager, DEVCOM Army Research Lab, Strategic Partnerships Office’s Paul Reid; Boston University’s Michelle Sander; Teledyne FLIR’s Stephen Se; Morgridge Institute for Research’s Melissa Skala; European Space Agency’s Zoran Sodnik; RIKEN Institute’s Masao Takamoto; the United States Army SBIR|STTR Program Manager, Office of the Assistant Secretary of the Army for Acquisition, Logistics, and Technology’s Zeke Topolosky; the Howard Hughes Medical Institute Janelia Research Campus’ Meng Wang; University of Queensland’s Andrew White; Duke University’s Junjie Yao; and University of California at Davis’ Robert Zawadzki.

Alongside the conferences and exhibitions, Photonics West will also offer 60 technical courses, including 13 new courses on topics such as optical imaging signals using machine learning, 2D to 3D integrated circuits, Fourier optics, practical optics for working technicians, and — in alignment with the brand-new Vision Tech conference — camera noise sources. The wide-ranging educational program complements numerous professional development workshops and valuable networking opportunities for attendees.

New in 2026, the SPIE Career Hub will offer a dynamic suite of resources and opportunities designed to empower professionals at every career stage, including thematic networking, professional headshots, a job fair and job board, informative talks, career speed mentoring, mock interviews, resumé review, and more.

Co-located with Photonics West, SPIE will also host its third Global Business Forum on 19 January. This one-day event will focus on current and emerging trends across the international optics and photonics industry and markets and will provide actionable insights for business leaders, including the release of SPIE’s annual report on the state of the optics and photonics industry. Registration for the Global Business Forum is separate from Photonics West and will be available via the event website.

“Photonics West remains the premier event for the global optics and photonics community to present their research, hear about the latest innovations from the world’s top research labs, and to engage and network with peers,” said SPIE Senior Director of Science, Technology & Industry Programs Bob Hainsey. “With an insightful industry program, our new Vision Tech conference and exhibition, and a terrific slate of speakers from across the geographic and technical spectrum, Photonics West 2026 will once again be the most important event of the year on the optics and photonics calendar.”

For more information and to register, please visit https://spie.org/pw.

About SPIE

SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, we have invested more than $25 million in the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251001765437/en/

Contacts

Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@spie.org -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbsky.app%2Fpro
file%2Fspie.org&esheet=54332615&newsitemid=20251001765437&lan=en-US&anchor=%40sp
ie.org&index=21&md5=8a5445f132b8c78faa99f6b77736c055

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye